CA2238029A1 - Procedes therapeutiques combinatoires utilisant des piegeurs de monoxyde d'azote et compositions utiles dans ces procedes - Google Patents

Procedes therapeutiques combinatoires utilisant des piegeurs de monoxyde d'azote et compositions utiles dans ces procedes Download PDF

Info

Publication number
CA2238029A1
CA2238029A1 CA002238029A CA2238029A CA2238029A1 CA 2238029 A1 CA2238029 A1 CA 2238029A1 CA 002238029 A CA002238029 A CA 002238029A CA 2238029 A CA2238029 A CA 2238029A CA 2238029 A1 CA2238029 A1 CA 2238029A1
Authority
CA
Canada
Prior art keywords
nitric oxide
inhibitors
agents
substituted
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002238029A
Other languages
English (en)
Inventor
Ching-San Lai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medinox Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2238029A1 publication Critical patent/CA2238029A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à des procédés thérapeutiques combinatoires pour l'inactivation ou l'inhibition in vivo de la formation (soit directement soit indirectement) d'espèces qui induisent l'expression de la monoxyde d'azote synthétase, ainsi que la réduction des niveaux de monoxyde d'azote produits à la suite de l'expression de .NO synthétase. A la différence de l'approche par inhibition de l'état actuel de la technique (où la fonction des enzymes responsables de la production du monoxyde d'azote est inhibée), cette invention utilise une combinaison de l'approche par inactivation (ou inhibition) et par piégeage, où le stimulus de l'expression de la monoxyde d'azote synthétase est inactivé, ou sa production est inhibée, et le monoxyde d'azote produit en excédent est fixé in vivo à un piégeur de monoxyde d'azote approprié. Les complexes qui en résultent rendent inactif le stimulus de l'expression de la monoxyde d'azote synthétase (ou inhibent sa production) et rendent inoffensif le monoxyde d'azote. Ces complexes finissent par être excrétés dans l'urine de l'organisme hôte. Dans un autre de ses aspects, cette invention se rapporte à la réduction des niveaux de monoxyde d'azote élevés associés à des états infectieux et/ou inflammatoires (et au traitement de ces états), grâce à l'utilisation d'un procédé thérapeutique combinatoire dans lequel un agent pour le traitement de ces états infectieux et/ou inflammatoires est administré conjointement à un composé de dithiocarbamate comme piégeur du monoxyde d'azote produit en excédent. Cette invention se rapporte en outre à des compositions et à des formulations utiles pour réaliser les procédés décrits ci-dessus.
CA002238029A 1996-03-05 1997-03-05 Procedes therapeutiques combinatoires utilisant des piegeurs de monoxyde d'azote et compositions utiles dans ces procedes Abandoned CA2238029A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1282096P 1996-03-05 1996-03-05
US60/012,820 1996-03-05

Publications (1)

Publication Number Publication Date
CA2238029A1 true CA2238029A1 (fr) 1997-09-12

Family

ID=21756859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002238029A Abandoned CA2238029A1 (fr) 1996-03-05 1997-03-05 Procedes therapeutiques combinatoires utilisant des piegeurs de monoxyde d'azote et compositions utiles dans ces procedes

Country Status (4)

Country Link
JP (1) JP2000506170A (fr)
AU (1) AU2213197A (fr)
CA (1) CA2238029A1 (fr)
WO (1) WO1997032585A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2230581T3 (es) * 1996-10-14 2005-05-01 Aventis Pharma Deutschland Gmbh Utilizacion de antagonistas no peptidicos de la bradiquinina en la preparacion de medicamentos para el tratamiento y prevencion de la enfermedad de alzheimer.
US6673807B1 (en) * 1998-04-06 2004-01-06 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
IL139783A0 (en) 1998-06-01 2002-02-10 Shionogi & Co Cyanoiminoquinoxaline derivates
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
GB9908175D0 (en) * 1999-04-09 1999-06-02 Lilly Co Eli Method of treating neurological disorders
US6274627B1 (en) 1999-10-12 2001-08-14 Medinox, Inc. Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
DE10230752A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis von Magnesiumsalzen und Fibrinolytika
AU2003259381A1 (en) * 2002-08-29 2004-03-19 University Of Southampton Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
WO2008038302A2 (fr) * 2006-09-26 2008-04-03 Jegannathan Srinivas Formulation thérapeutique comprenant une sulfonylurée, un biguanide, et une fraction libérant de l'oxyde nitrique qui est complexée avec un capteur de l'oxyde nitrique
WO2009052376A1 (fr) 2007-10-18 2009-04-23 Musc Foundation For Research Development Procédés de diagnostic d'un cancer génito-urinaire

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426046A (en) * 1983-11-08 1995-06-20 The Board Of Trustees Of The Leland Stanford Junior University Human monoclonal antibody to lipid A of gram negative bacteria
US5137889A (en) * 1983-12-02 1992-08-11 Otsuka Pharmaceutical Co., Ltd. Dihydropyridine derivatives and process for preparing the same
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
ATE109970T1 (de) * 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US5294430A (en) * 1988-09-12 1994-03-15 University Of Rochester Use of dithiocarbamates to treat myelosuppression
US5176908A (en) * 1988-12-19 1993-01-05 American Cyanamid Company Method for the treatment of endotoxic shock in mammal
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5530141A (en) * 1992-03-04 1996-06-25 Center For Innovative Technology 2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diaryl-1,3-oxathiolanes; and 2,5-diaryl-1,3-oxathiolanes for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5460954A (en) * 1992-04-01 1995-10-24 Cheil Foods & Chemicals, Inc. Production of human proinsulin using a novel vector system
AU3803593A (en) * 1992-04-02 1993-11-08 Smithkline Beecham Corporation Compounds
US5317040A (en) * 1993-01-26 1994-05-31 Washington University Method for the treatment of pertussis with aminoguanidine
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents

Also Published As

Publication number Publication date
JP2000506170A (ja) 2000-05-23
AU2213197A (en) 1997-09-22
WO1997032585A1 (fr) 1997-09-12

Similar Documents

Publication Publication Date Title
US5747532A (en) Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
CA2238029A1 (fr) Procedes therapeutiques combinatoires utilisant des piegeurs de monoxyde d'azote et compositions utiles dans ces procedes
AU657212B2 (en) Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US6589991B1 (en) Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
AU703952B2 (en) Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
AU741835B2 (en) Methods for in vivo reduction of iron levels and compositions useful therefor
AU746790B2 (en) Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
US6469057B1 (en) Methods for in vivo reduction of free radical levels and compositions useful therefor
JP2009535410A (ja) ピロロキノリンキノンおよびその使用
US20030181495A1 (en) Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
WO2014189789A1 (fr) Traitement d'une hypotension associée à une hémodialyse
Schmaldienst et al. Bacterial infections during immunosuppression-immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function
Atalay et al. The effects of nitric oxide donors and inhibitors on neutrophil functions in Behçet's disease
Field et al. Reversal of Nitrogen Mustard Intoxication by a Serotonin Antagonist.
AU722361B2 (en) Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
TW516957B (en) Composition for use in reducing nitric oxide levels and inactivating or inhibiting the formation of species that induce the expression of nitric oxide synthase
JP2000007562A (ja) レトロウイルス感染に伴う免疫不全発症予防薬及び進行抑制薬
Williams et al. Glomerular Basement Membrane and the Inflammatory Response
JP2001508087A (ja) トランスフェリングリカンを主成分とする正常化栄養薬組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead